Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Core Insights - Anixa Biosciences, Inc. is set to present additional data from its Phase 1 clinical trial of a breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting on November 8, 2024 [1][2] - The vaccine targets the α-lactalbumin protein, which is present in certain breast cancers but absent in normal aging tissues post-lactation, aiming to activate the immune system for preemptive protection against breast tumors [3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program and various cancer vaccines developed in collaboration with Cleveland Clinic [7] - The breast cancer vaccine technology was developed by Dr. Vincent Tuohy at Cleveland Clinic, and Anixa holds the exclusive worldwide license for this technology [5][6] Clinical Trial Details - The Phase 1 trial is conducted in collaboration with Cleveland Clinic and funded by a grant from the U.S. Department of Defense, with initial data showing no safety concerns and immune responses in a majority of patients [4][5] - The upcoming presentation will provide further analysis of the trial data, which was initially presented at the San Antonio Breast Cancer Symposium in December 2023 [4][2]